The need and potential of patient-specific modelling

C. Brightling (Leicester, United Kingdom)

Source: Annual Congress 2012 - PG13 AirPROM: patient-specific modelling and systems biology living labs workshop
Session: PG13 AirPROM: patient-specific modelling and systems biology living labs workshop
Session type: Postgraduate Course
Number: 125

Slide presentationPDF journal article, handout or slidesMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Brightling (Leicester, United Kingdom). The need and potential of patient-specific modelling. Annual Congress 2012 - PG13 AirPROM: patient-specific modelling and systems biology living labs workshop

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The potential of modelling
Source: International Congress 2014 – AirPROM: can imaging and modelling take us beyond FEV1?
Year: 2014



Leveraging causal modeling to predict future COPD
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021


The evaluation of frequency dependence of resistance using a patient-specific 3D physical model and a computational model
Source: International Congress 2017 – Lung function testing in different patient categories
Year: 2017

Which modelling methodology is best?
Source: ERS Research Seminar 2017 – The impact of air pollution on respiratory health
Year: 2018


Halotherapy and Covid-19: an oppinion for a possible future prevention approach
Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors
Year: 2021


Features of asthma management: quantifying the patient‘s perspective using discrete choice modelling
Source: Eur Respir J 2006; 28: Suppl. 50, 122s
Year: 2006

Applying new respiratory function technologies to the elderly and the potential of future lung regeneration
Source: Virtual Congress 2020 – Lung health and respiratory function at all ages
Year: 2020


Developing a novel in vitro 3D airway model to provide a viable alternative to animal use in asthma research
Source: Annual Congress 2012 - Cell culture and animal models of lung disease
Year: 2012

What regulatory framework is preferable for successful harm reduction?
Source: Research Seminar 2005 - Tobacco Smoking: Harm Reduction Strategies
Year: 2005

There is no rationale to still rely on outdated, biased tools for quantitative morphology in pulmonary research
Source: Eur Respir Rev 2006; 15: 105-106
Year: 2006


Methodological approach to the development of a learning needs assessment tool
Source: International Congress 2018 – Acutely hospitalised patients: physiotherapy interventions and assessment methods
Year: 2018


Individualised field testing is a useful tool to evaluate difficult asthma.
Source: International Congress 2017 – Diagnostic tools and comorbidities in paediatric asthma
Year: 2017


HOPE-BAL: A novel tool to expand the methodological capabilities in pulmonary research
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012


What do we need in the clinic and what approach can clinicians take to improve the drug development pipeline?
Source: ERS Research Seminar 2016
Year: 2016

Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017



Do we need a gender-specific approach for health interventions?
Source: Virtual Congress 2021 – Highlights on gender and respiratory health
Year: 2021


Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020
Year: 2020